Publication

Cutaneous Leishmaniasis in Saudi Arabia: A Comprehensive Overview

Downloadable Content

Persistent URL
Last modified
  • 03/05/2025
Type of Material
Authors
    Abuzaid A. Abuzaid, Ministry of Health, RiyadhAbdalmohsin M. Abdoon, Ministry of Health, RiyadhMohamed A. Aldahan, Ministry of Health, RiyadhAbdullah G. Alzahrani, Ministry of Health, RiyadhRaaft F. Alhakeem, Ministry of Health, RiyadhAbdullah M. Asiri, Ministry of Health, RiyadhMohamed H. Alzahrani, Ministry of Health, RiyadhZiad Memish, Emory University
Language
  • English
Date
  • 2017-08-14
Publisher
  • Mary Ann Liebert
Publication Version
Copyright Statement
  • © Abuzaid A. Abuzaid et al. 2017; Published by Mary Ann Liebert, Inc.
License
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 1530-3667
Volume
  • 17
Issue
  • 10
Start Page
  • 673
End Page
  • 684
Abstract
  • Despite the great efforts by health authorities in Kingdom of Saudi Arabia (KSA), Cutaneous leishmaniasis (CL) continues to be a major public health problem in the country. Many risk factors make KSA prone to outbreaks and epidemics; among these, rapid urbanization and the huge population movement are the most important. The disease is endemic in many parts of KSA, with the majority of cases concentrated in six regions, including Al-Qaseem, Riyadh, Al-Hassa, Aseer, Ha'il, and Al-Madinah. Leishmania major (L. major) and Leishmania tropica (L. tropica) are the main dermotropic species, and Phlebotomus papatasi (vector of L. major) and Phlebotomus sergenti (vector of L. tropica) are the proved vectors of the disease. Psammomys obesus and Meriones libycus have been defined as the principal reservoir hosts of zoonotic CL in Al-Hassa oasis, Al-Madinah, and Al-Qaseem provinces. Clinically, males are affected more than females, and there is no variation between the Saudis and expatriates in terms of number of reported cases, but the disease tends to run a more severe course among non-Saudis. Face is the most commonly affected site, and ulcerative pattern accounts for 90% of lesions. Despite local and international recommendations of using laboratory diagnostics to confirm CL cases, most cases in KSA are diagnosed and treated on clinical grounds and local epidemiology. However, systemic parenteral sodium stibogluconate (SSG) is the first line of therapy and used to treat all CL patients irrespective of their clinical presentation or the incriminated species. In brief, more efforts are needed to combat this disease. Several aspects of the disease require more evaluation through encouragement of national and regional studies. Development of evidence based national diagnostic and management guidelines, as well as algorithms, is urgently needed to improve the practice of diagnosing and treating CL in KSA.
Author Notes
  • Address correspondence to:, Abuzaid A. Abuzaid, Infectious Diseases Control Directorate, Ministry of Health, King Abdulaziz Street, Riyadh 11111, Kingdom of Saudi Arabia, E-mail:Email: abuzaidabdalla@yahoo.com
Keywords
Research Categories
  • Health Sciences, Public Health
  • Health Sciences, Epidemiology

Tools

Relations

In Collection:

Items